Pegylated liposomal doxorubicin in ovarian cancer

(2505) Views  (472) Full article downloads

Authors: Andrew E Green, Peter G Rose

Published Date May 2006 Volume 2006:1(3) Pages 229 - 239

DOI: http://dx.doi.org/10.2147/IJN.S

Andrew E Green, Peter G Rose

Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, OH, USA

Abstract: Pegylated liposomal doxorubicin is a formulation of doxorubicin in which the molecule itself is packaged in a liposome made of various lipids with an outer coating of polyethylene glycol. Liposomal technology is being used in increasing amounts in the therapy of a variety of cancers, including ovarian cancers. This article reviews the mechanistic actions of this formulation, the Phase II and Phase III data that helped define the role of pegylated liposomal doxorubicin in recurrent ovarian cancer, as well as a discussion of some of the side-effects and their management.

Keywords: pegylated lipopsomal doxorubicin, ovarian cancer